EUCTR2014-004432-18-NL进行中（未招募）1 期
Activity of trastuzumab based chemotherapy in metastatic breast patients with HER2-negative primary tumor but HER2 positive circulating tumor cells (CareMore-Trastuzumab)
Erasmus MC Cancer Institute0 个研究点目标入组 37 人开始时间: 2014年11月27日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Female patient with metastatic breast cancer with HER2-negative primary tumor
- •Age = 18 years old
- •WHO performance status =2
- •Considered fit enough to receive trastuzumab/docetaxel by the treating physician
- •Able to understand and give written informed consent
- •Secondary inclusion criteria
- •Female patient with metastatic breast cancer with HER2-negative primary tumors with the presence of at least one HER2-positive CTC
- •Adequate left-ventricular ejection fraction (LVEF) of at least 45%
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 7
排除标准
- •Previous chemotherapy for metastatic disease.
- •Adjuvant chemotherapy within 6 months prior to treatment start.
- •Hormonal antitumor treatment within one week prior to treatment start.
- •Symptomatic CNS metastases
研究者
相似试验
进行中（未招募）
不适用
Efficacy and toxicity of Trastuzumab at the maintaining dose of 1 mg/kg/week versus the standard dose of 2 mg/kg/week in combination with chemotherapy in metastatic breast cancer patients. A phase III multicenter study. - Dose optimization of TrastuzumabEUCTR2007-006060-29-ITIST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO
已完成
2 期
The effect of anti-HER2 therapy in metastatic breast cancer wih HER2-negative primary tumor but HER2-positive circulating tumor cells<p>Breast cancer, borstkanker, HER2, ER, PIK3CA, CTC, circulating tumor cell, circulerende tumorcellen, metastasen, metastasis, trastuzumab, herceptin, docetaxel</p>10006232NL-OMON20549Erasmus MC Cancer Institute, department of Medical Oncology18
进行中（未招募）
1 期
Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain studyHER2- positive breast cancerMedDRA version: 23.0Level: PTClassification code: 10065430Term: HER2 positive breast cancer Class: 100000004864CTIS2023-509923-42-00Medica Scientia Innovation Research S.L.345
进行中（未招募）
1 期
Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain studyHER2-positive breast cancerMedDRA version: 19.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002676-27-ESMedica Scientia Innovation Research (MedSIR)400
进行中（未招募）
1 期
Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer after FDG-PET response-adapted strategy. The PHERGain studyHER2-positive breast cancerMedDRA version: 20.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002676-27-FRMedica Scientia Innovation Research (MedSIR)400